Safety and Efficacy of MK-5172 + MK-8742 in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052/C-SURFER)

Conditions

Hepatitis C Virus

What is the purpose of this trial?

This study will evaluate the safety and efficacy of combination treatment with MK-5172 + MK-8742 for non-cirrhotic participants with chronic Genotype 1 (GT1) hepatitis C virus (HCV) infection and chronic kidney disease (CKD). After a screening period, participants will receive random assignment to one of two study arms (immediate treatment or deferred treatment,) or assignment to open-label immediate treatment with intensive pharmacokinetic sampling. The primary study hypothesis is that the proportion of participants achieving a sustained viral response 12 weeks after the end of all study treatment (SVR12) will be >;45%.


Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Merck Sharp & Dohme
Dates:
04/16/2014
Last Updated:
Study HIC#:
1402013464